Filing Flows › cbdMD (YCBD) › Takeover & LBO
Is cbdMD (YCBD) a takeover target?
A leveraged buyout does not work for cbdMD on its latest figures: the figures a buyout model needs (revenue, EBITDA, the share count and the price) are not all on file. Latest signal (2026-11-04): cbdMD Completes Acquisition of the Operating Assets and Brands of Twinlab, including Twinlab, Reserveage and Metabolife Brands, Expanding Into Broader Wellness.
Why a leveraged buyout does not fit
The buyout model needs cbdMD's revenue, EBITDA, share count and share price; not all of them are on file, so it gives no buyout price.
What a takeover could cost
Takeovers on record paid a median premium of 32.5% over the share price before the deal (the middle half 20% to 51.8%), according to the 1,437 merger proxies and tender-offer responses on EDGAR that state a premium.
Rumors and deal signals
- 2026-11-04 · 8-K deal · cbdMD Completes Acquisition of the Operating Assets and Brands of Twinlab, including Twinlab, Reserveage and Metabolife Brands, Expanding Into Broader Wellness
cbdMD's latest quarter
cbdMD, Q3 FY26: revenue $5.6M (+21% year over year), operating margin -20.4%, net loss $1.1M, operating cash flow −$442K. The chart follows the revenue to costs, profit and cash.
Questions
Is cbdMD being acquired?
The latest signal on file is from 2026-11-04: cbdMD Completes Acquisition of the Operating Assets and Brands of Twinlab, including Twinlab, Reserveage and Metabolife Brands, Expanding Into Broader Wellness. A headline is not a deal; Filing Flows lists the news, 8-K filings and 13D filings about a sale.
Could private equity buy cbdMD?
A leveraged buyout does not work for cbdMD on its latest figures: the figures a buyout model needs (revenue, EBITDA, the share count and the price) are not all on file. The model gives no buyout price until they are.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.